Bucillamine Study of Holding Remission After Infliximab Dose-off
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients with rheumatoid arthritis who have been well controlled with methotrexate plus
infliximab may remain in remission or low disease activity without infliximab. And the chance
of sustained remission increase by the addition of another DMARD, bucillamine, at the time of
discontinuing infliximab. The BuSHIDO trial is the prospective, randomized, controlled study
comparing MTX monotherapy and MTX plus bucillamine combination therapy as to the rate of
disease flare after discontinuing infliximab.